D-dimer Testing Market Size, Share & Trends Analysis Report By Product, By Test Type (Clinical Laboratory, POC), By Method (ELISA, LETIA, FIA), By Application (DVT, PE, DIC), By End Use, By Region, And Segment Forecasts, 2025 - 2030

D-dimer Testing Market Size, Share & Trends Analysis Report By Product, By Test Type (Clinical Laboratory, POC), By Method (ELISA, LETIA, FIA), By Application (DVT, PE, DIC), By End Use, By Region, And Segment Forecasts, 2025 - 2030

D-dimer Testing Market Growth & Trends

The global D-dimer testing market size is expected to reach USD 2.46 billion in 2030 and is projected to grow at a CAGR of 4.5% from 2025 to 2030. Technological advancements in D-dimer testing have resulted in the development of a wide range of products that have allowed healthcare professionals to offer suitable emergency assistance to patients. The concept of automation in D-dimer testing has provided rapid, less labor-intensive, and user-friendly diagnostic strategies, which is expected to drive the market in the near future.

The commercially available assays often have differences in their antibody specificity as D-dimer antibodies also detect Fibrin Degradation Products (FDPs), leading to incorrect results. To address this issue, Advanced ImmunoChemical, Inc. has developed two monoclonal antibodies, which are used to design one-step immunoassay specific for both FDP and D-dimer. Thus, the development of improved immunoassays that equally detect all FDPs is expected to boost the market growth.

Extensive research for the determination of new D-dimer threshold values for a specific population set prevents the usage of Computed Tomography Pulmonary Angiography (CTPA). This is beneficial as the elimination of CTPA leads to low radiation exposure, which, in turn, increases the demand for the test. To demonstrate this, a group of researchers from Japan determined new elevated D-dimer threshold values for the diagnosis of pulmonary embolism in the Japanese population. Such studies are expected to favor market growth.

D-dimer Testing Market Report Highlights

• Reagents and consumables accounted for the largest revenue share in 2024 owing to the wide availability and frequent usage of reagents in the market space
• Presence of blocking agents that reduce the interferences from heterophilic antibodies to increase the efficiency of immunoassays boost the reagents and consumables segment
• Shorter turnaround times, ease of use, and generation of gold-standard quality results are among the few factors that lead to a lucrative growth of point-of-care testing
• Enzyme-linked Immunosorbent Assays (ELISA) held the largest revenue share because microplate ELISA is considered as a reference method due to its high sensitivity for coagulation markers
• Deep Vein Thrombosis (DVT) dominated the revenue share in 2024 as this test is a reliable method and is used as a routine screening test for DVT
• The hospitals' segment accounted for the maximum revenue share in 2024
• This is attributive to a rise in the rate of pulmonary embolism cases in hospitalized patients, which results in high adoption of the test in hospitals
• Asia Pacific is expected to witness a lucrative CAGR due to a rise in the funding initiatives that support research studies related to the usage of these assays in various diseases
• The National Natural Science Foundation of China and the Fundamental Research Funds for the Central Universities are among the few agencies involved in funding research studies in China
• Key companies operating in the market have undertaken several growth initiatives to expand their product portfolio
• For instance, in February 2019, HORIBA introduced the Yumizen D-Dimer reagent kit for measurement and reference exclusion testing for DVT and pulmonary embolism.

Please note The report will be delivered in 2-3 business days upon order notification.